NCT05950906View on ClinicalTrials.gov

Study to Assess PDM608 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

March 17, 2024

Study Completion Date

April 19, 2024

Conditions
Parkinson Disease
Interventions
DRUG

PDM608

PDM608 subcutaneous at single or multiple dose(s) assigned by cohort

DRUG

Placebo

Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.

Trial Locations (1)

33126

Quotient Sciences-Miami, Inc, Miami

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

collaborator

Alzheimer's Drug Discovery Foundation

OTHER

lead

Calibr, a division of Scripps Research

OTHER

NCT05950906 - Study to Assess PDM608 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter